ArticleFrontiers in toxicology2025
A new type of ultrasonic water alleviates constipation with favorable safety.
Article in Frontiers in toxicology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Ultrasonic water (UW) is a novel category of functional drinking water. This study aimed to investigate its laxative efficacy and underlying mechanisms using a constipation model in SD rats, while also conducting a comprehensive safety evaluation. Methods: A rat constipation model was established to assess the purgative effect of UW. Safety was systematically evaluated through acute oral toxicity tests, subacute oral toxicity tests, a bone marrow cell micronucleus test, and an Ames test. Serum levels of gastrointestinal hormones-including motilin, substance P, vasoactive intestinal peptide, acetylcholinesterase, and somatostatin-were measured to explore potential mechanisms. Results and discussion: UW significantly improved constipation symptoms of the test SD rats, with a significant increase in body weight (16.03 ± 5.32%) compared to the model group (8.67 ± 4.02%, P < 0.05). Compared to the model group, serum levels of excitatory gastrointestinal hormones were significantly elevated 4.20% (motilin), 10.87% (substance P), 36.69% (vasoactive intestinal peptide) and 12.89% (acetylcholinesterase) (P < 0.05), while somatostatin, was markedly reduced 22.40% (P < 0.05), respectively. Acute oral LD50 values of UW were higher than 20000 mg/kg, indicating practical non-toxicity. In the subacute toxicity test, compared to those in the control group, performances, blood routine indexes and serum biochemical indexes of the rats in the UW group showed no statistical difference (P > 0.05), and all the organs and tissues of the rats in both groups maintained normal morphology. Micronucleus effect of UW was not found when the dosage of UW was up to 20000 mg/kg. UW also showed no mutagenic activity on standard test strains. In summary, UW exhibited favorable purgative effect and safety.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.